Antibodies 2013, 2(1), 113-129; doi:10.3390/antib2010113
Review

Antibody Drug Conjugates as Cancer Therapeutics

Regeneron Pharmaceuticals, Tarrytown, NY 10591, USA
Received: 24 December 2012; in revised form: 11 February 2013 / Accepted: 18 February 2013 / Published: 27 February 2013
(This article belongs to the Special Issue Antibody-Drug Conjugates)
PDF Full-text Download PDF Full-Text [336 KB, uploaded 27 February 2013 08:21 CET]
Abstract: Monoclonal antibody (MAb) based therapies have achieved considerable success in oncology, primarily when used in combination with cytotoxic drugs. Antibody drug conjugates (ADCs) are a class of therapeutics that harness the antigen-selectivity of MAbs to deliver highly potent cytotoxic drugs to antigen-expressing tumor cells. The use of MAb directed delivery can confer a therapeutic index to highly potent cytotoxic drugs, increasing both the efficacy and safety of therapy. Although simple in concept, to achieve the design goal of improved therapeutic efficacy and reduced toxicity, each of the components of an ADC; the MAb, linker and drug need to considered in the context of the targeted antigen, the selectivity of antigen expression and the biology of the tumor type on which the target antigen is expressed. The characteristics of targets, MAbs, linkers and drugs being used in ADC design are discussed.
Keywords: antibody drug conjugate; ADC; immunoconjugate; antibody; cytotoxic; cancer; drug delivery

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Trail, P.A. Antibody Drug Conjugates as Cancer Therapeutics. Antibodies 2013, 2, 113-129.

AMA Style

Trail PA. Antibody Drug Conjugates as Cancer Therapeutics. Antibodies. 2013; 2(1):113-129.

Chicago/Turabian Style

Trail, Pamela A. 2013. "Antibody Drug Conjugates as Cancer Therapeutics." Antibodies 2, no. 1: 113-129.

Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert